BALAD-2 Emerges as the Most Accurate Prognostic Model in Hepatocellular Carcinoma: Results from a Biobank-Based Cohort Study
Authors:
- Coskun Ozer DemirtasCDCoskun Ozer Demirtas
- Fatih ErenFEFatih Eren
- Demet Yilmaz KaradagDKDemet Yilmaz Karadag
- Yasemin Kaldirim ArmutcuogluYAYasemin Kaldirim Armutcuoglu
- Tugba ToluTTTugba Tolu
- Javid HuseyinovJHJavid Huseyinov
- Ugur CiftciUCUgur Ciftci
- Tuba YilmazTYTuba Yilmaz
- Sehnaz AkinSASehnaz Akin
- Feyza DilberFDFeyza Dilber
- Osman Cavit OzdoganOOOsman Cavit Ozdogan
Open Access
Abstract
Background/Objectives: Accurate prognostication of hepatocellular carcinoma (HCC) remains essential for treatment selection and risk stratification. This study aimed to compare the prognostic performance of individual serum biomarkers and composite scoring models, including GALAD, BALAD, BALAD-2, GAAP, ASAP, the Doylestown algorithm, and aMAP, using data from a biobank-based HCC cohort. Methods: This study enrolled 186 patients with confirmed HCC diagnosed between 2019 and 2024. Serum biomarkers (AFP, AFP-L3%, DCP) and composite models were evaluated for their association with overall survival (OS). Prognostic performance was assessed using time-dependent area under the receiver operating characteristic curve (AUROC) at 1-, 2-, 3-, and 5-year intervals and Harrel’s concordance index (c-index). Subgroup analyses were performed based on treatment intent and liver disease etiology. Results: All three biomarkers and composite models were independently associated with OS in multivariate analyses (all p < 0.05). Among all models, BALAD-2 demonstrated the best overall performance (c-index: 0.737), with the highest AUROCs at 1 year (0.827), 2 years (0.846), 3 years (0.781), and 5 years (0.716). BALAD-2 consistently showed superior discrimination in patients treated with curative or noncurative therapies and in the viral etiology subgroup. In the non-viral etiology subgroup, BALAD-2 remained among the top performers, although the GAAP, ASAP, and Doylestown algorithms showed slightly higher metrics. Conclusions: BALAD-2 demonstrated consistent and robust prognostic performance compared with other biomarker-based and clinical models across different patient subgroups, particularly among those receiving curative therapy and viral etiologies. These findings support its integration into clinical risk stratification and decision-making for HCC management.Keywords
Funding Information
- Fujifilm Company
This publication has 35 references indexed in Scilit:
- Prognostic Value of the ASAP Score for Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma: A Multicenter Analysis of 1,239 PatientsJournal of Clinical and Experimental Hepatology, 2024
- The aMAP score predicts long-term outcomes after resection of hepatocellular carcinoma: a multi-institutional analysisHPB, 2024
- GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosisHepatology, 2021
- Proposal and Validation of a Novel Scoring System for Hepatocellular Carcinomas Beyond Curability BordersHepatology Communications, 2021
- BALAD and BALAD-2 predict survival of hepatocellular carcinoma patients: a North American cohort studyHPB, 2020
- Validation of serological models for staging and prognostication of HCC in patients from a Japanese nationwide surveyJournal of Gastroenterology, 2017
- Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in PatientsClinical Gastroenterology and Hepatology, 2016
- Automated immunoassay system for AFP–L3% using on-chip electrokinetic reaction and separation by affinity electrophoresisAnalytical Biochemistry, 2009
- Lens culinaris agglutinin-reactive α-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinomaJournal of Gastroenterology, 2007
- Staging Hepatocellular Carcinoma by a Novel Scoring System (BALAD Score) Based on Serum MarkersClinical Gastroenterology and Hepatology, 2006